Literature DB >> 14519513

Pharmacokinetics and pharmacodynamics of L-arginine in rats: a model of stimulated neuronal nitric oxide synthesis.

Erin L Heinzen1, Gary M Pollack.   

Abstract

Nitric oxide (NO) is believed to be involved in a variety of central nervous system (CNS) functions, including opioid responsivity. Elucidation of the role of NO in the CNS requires the ability to elevate systematically neuronal NO concentrations in vivo. This study was conducted to assess the pharmacokinetics of L-arginine, a NO precursor, and to relate the disposition of this amino acid to the pharmacodynamic endpoint of neuronal NO production. L-Arginine (250-, 500-, or 1000-mg/kg/h) or saline was infused intravenously for 6 h to rats. L-Arginine was quantified in brain and blood (after in vivo microdialysis) with high-performance liquid chromatography. NO was quantified simultaneously with a sensitive and specific amperometric sensor placed in the hippocampus. The data were fit with a comprehensive pharmacokinetic-pharmacodynamic (PK/PD) model to obtain parameters governing the systemic disposition of L-arginine, the uptake of L-arginine into the brain, and subsequent NO production. Exogenous administration of L-arginine resulted in incremental elevations in hippocampal NO, with a approximately 33, 48, and approximately 50% increase from control for the 250-, 500-, and 1000-mg/kg/h L-arginine treated rats, respectively. The PK/PD model, which incorporated known characteristics of the system (saturable uptake of L-arginine into brain; NO production governed by circadian changes in enzyme activity) was capable of describing accurately the observed data. The model developed herein will be invaluable in characterizing the numerous roles of NO in the CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519513     DOI: 10.1016/s0006-8993(03)03370-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

1.  Involvement of NO/cGMP pathway in toluene-induced locomotor hyperactivity in female rats.

Authors:  Ming-Huan Chan; Te-Hsiung Chien; Pei-Yu Lee; Hwei-Hsien Chen
Journal:  Psychopharmacology (Berl)       Date:  2004-04-29       Impact factor: 4.530

2.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

3.  Lamotrigine differently modulates 7-nitroindazole and L-arginine influence on rat maximal dentate gyrus activation.

Authors:  P Sardo; S D'Agostino; F Carletti; V Rizzo; V La Grutta; G Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

4.  In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs.

Authors:  Pierangelo Sardo; Stefania D'Agostino; Valerio Rizzo; Fabio Carletti; Gioacchino Lonobile; Giuseppe Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

Review 5.  Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review.

Authors:  Jahidur Rashid; Shaun S Kumar; Kathleen M Job; Xiaoxi Liu; Candice D Fike; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2020-06       Impact factor: 3.022

6.  Modulatory effects of nitric oxide-active drugs on the anticonvulsant activity of lamotrigine in an experimental model of partial complex epilepsy in the rat.

Authors:  Pierangelo Sardo; Giuseppe Ferraro
Journal:  BMC Neurosci       Date:  2007-07-03       Impact factor: 3.288

7.  The Relationship Between Creatine and Whey Protein Supplements Consumption and Anesthesia in Rats.

Authors:  Kianoush Saberi; Mohammad Amin Gorji Mahlabani; Mohammad Tashayoie; Farinaz Nasiri Nejad
Journal:  Anesth Pain Med       Date:  2016-02-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.